GlassScriptPhysician profile
Jeffrey Myatt
NPI 1679850465
$3,618.55
in general payments reported to CMS, 2019-2025
46 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $450 · 2023: $517 · 2024: $1,226 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $281.83 | 2021-2023 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $203.16 | 2024-2025 | |
| Pfizer INC. | $184.17 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $177.16 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $175.33 | 2023-2024 | Lifevest |
| Vertos Medical, INC. | $168.74 | 2021 | |
| Medtronic, INC. | $144.32 | 2022-2023 | Micra |
| Relievant Medsystems, INC. | $124.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $120.70 | 2022-2024 | Xarelto |
| Vanda Pharmaceuticals INC. | $114.10 | 2022-2023 | Hetlioz |
| Abbvie INC. | $113.87 | 2021-2022 | |
| Amgen INC. | $111.64 | 2022-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $111.05 | 2024-2025 | Amvuttra, Onpattro |
| Atricure, INC. | $109.85 | 2024-2025 | Atriclip Laa Exclusion System |
| Merz Pharmaceuticals, LLC | $100.97 | 2021-2023 | Xeomin |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Myatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.